Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug ‘donanemab’ would only be the second Alzheimer’s drug cleared in the United States. to slow cognitive decline due to Alzheimer’s. Katherine Ward has this story and more in Health Matters for June 11, 2024.
Health Matters
Health Matters: U.S. FDA advisers endorse Alzheimer’s drug
More Videos
-
Health Matters: Health Canada approves chikungunya vaccine
-
Health Matters: Patients hope help, awareness increase for those with stiff person syndrome
-
Health Matters: Researchers identify genetic obesity trigger
-
Health Matters: Students sweltering in Ontario, Quebec as many schools are without air conditioning
-
Health Matters: Medical risks associated with certain medications in extreme heat
-
Health Matters: Extreme heat hits millions across Canada, US
You are viewing an Accelerated Mobile Webpage.
View Original Article